PD-L1 and tumor-associated macrophages in de novo DLBCL.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
B7-H1 Antigen
/ analysis
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Macrophages
/ drug effects
Male
Middle Aged
STAT3 Transcription Factor
/ genetics
Treatment Outcome
Young Adult
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
26 02 2019
26 02 2019
Historique:
received:
03
05
2018
accepted:
02
01
2019
entrez:
17
2
2019
pubmed:
17
2
2019
medline:
3
3
2020
Statut:
ppublish
Résumé
Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death-1 (PD-1), are important negative regulators of immune cell activation. Therapeutically targeting PD-1/PD-L1 in diffuse large B-cell lymphoma (DLBCL) patients with a single agent has limited activity, meriting a deeper understanding of this complex biology and of available PD-L1 clinical assays. In this study, we leveraged 2 large de novo DLBCL phase 3 trials (GOYA and MAIN) to better understand the biologic and clinical relevance of PD-L1 in de novo DLBCL. PD-L1 was expressed on myeloid cells in 85% to 95% of DLBCL patients (depending on staining procedure), compared with 10% on tumor cells, and correlated with macrophage gene expression. PD-L1 did not identify high-risk patients in de novo DLBCL; it correlated with
Identifiants
pubmed: 30770362
pii: bloodadvances.2018020602
doi: 10.1182/bloodadvances.2018020602
pmc: PMC6391660
doi:
Substances chimiques
Antineoplastic Agents
0
B7-H1 Antigen
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT01287741', 'NCT00486759']
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-540Informations de copyright
© 2019 by The American Society of Hematology.
Références
J Immunol. 2009 Apr 1;182(7):4415-22
pubmed: 19299742
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
pubmed: 12900505
Haematologica. 2014 Aug;99(8):1343-9
pubmed: 24895339
Genes Immun. 2005 Jun;6(4):319-31
pubmed: 15789058
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
Haematologica. 2015 Feb;100(2):143-5
pubmed: 25638802
Anticancer Res. 2017 Oct;37(10):5655-5666
pubmed: 28982883
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Histopathology. 2016 Jun;68(7):1079-89
pubmed: 26426431
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Blood. 2009 Sep 24;114(13):2721-9
pubmed: 19633198
J Clin Oncol. 2009 Mar 20;27(9):1470-6
pubmed: 19224853
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
Hum Pathol. 2016 Aug;54:17-24
pubmed: 27045512
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
Leukemia. 2017 Apr;31(4):988-991
pubmed: 28035137
Blood Adv. 2017 Sep 27;1(22):1884-1890
pubmed: 29296835
Clin Cancer Res. 2011 Jul 1;17(13):4232-44
pubmed: 21540239
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cancer Sci. 2016 Nov;107(11):1696-1704
pubmed: 27564404
Blood. 2015 Nov 5;126(19):2193-201
pubmed: 26239088
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100
pubmed: 29346180
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Hematol Oncol. 2015 Jun;33(2):110-2
pubmed: 24711044
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2017 Feb 21;8:14572
pubmed: 28220772
Haematologica. 2015 Feb;100(2):238-45
pubmed: 25381134
Br J Haematol. 2018 Mar;180(5):744-748
pubmed: 27879989
Hum Pathol. 2008 Jul;39(7):1050-8
pubmed: 18479731
J Exp Med. 2004 Jun 21;199(12):1659-69
pubmed: 15210744
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Blood. 2009 Oct 22;114(17):3625-8
pubmed: 19710503
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Clin Cancer Res. 2005 Apr 15;11(8):2947-53
pubmed: 15837746
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Blood. 2016 Aug 25;128(8):1081-92
pubmed: 27338100
Cancer Res. 2006 Apr 1;66(7):3381-5
pubmed: 16585157
J Immunol. 2005 Jan 15;174(2):817-26
pubmed: 15634903
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588